Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kelly James

Surgery Independence, MO Medical Doctor

NPI 1366428302 CMS profile 16536

19101 E Valley View Pkwy, Suite B, Independence, MO 64055

Open in the dashboard

General payments

$105,707

306 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,000 paid to institutions, not to them · program year 2024

Through program year 2025, Kelly James of Independence, MO is reported in the CMS Open Payments database as having received $105,707 across 306 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $5,000 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,892 33
2024 General $34,313 69
2023 General $17,261 36
2022 General $13,282 59
2021 General $461 13
2020 General $6,042 29
2019 General $20,456 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly James
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Kelly James were reported at $13,892. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Kelly James Surgery median Middle half National median
2019 $20,456 $253 $82–$1,521 $163
2020 $6,042 $131 $40–$706 $114
2021 $461 $168 $50–$904 $132
2022 $13,282 $224 $76–$1,218 $149
2023 $17,261 $253 $82–$1,255 $160
2024 $34,313 $279 $90–$1,381 $164
2025 $13,892 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $96,268 204 payments
  2. Aroa Biosurgery Incorporated $5,123 7 payments
  3. Senseonics, Incorporated $1,200 3 payments
  4. Organogenesis Inc. $988 28 payments
  5. Integra LifeSciences Corporation $531 18 payments
  6. Acera Surgical, Inc. $345 13 payments
  7. Ascensia Diabetes Care US Inc. $240 1 payment
  8. ConvaTec Inc. $198 1 payment
  9. Kerecis Limited $158 4 payments
  10. Wright Medical Technology, Inc. $114 1 payment
  11. Other $542 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $47,734 21 payments
  2. Consulting Fee $33,484 15 payments
  3. Travel and Lodging $16,672 73 payments
  4. Food and Beverage $7,816 197 payments
Products named General payments · program years 2019–2025
  1. PICO $38,750 62 payments
  2. OASIS $22,496 23 payments
  3. PICO Single Use Negative Pressure Wound Therapy $19,522 37 payments
  4. GRAFIX $16,031 16 payments
  5. GRAFIX PL $15,012 11 payments
  6. GRAFIX XC $14,728 6 payments
  7. ACTICOAT 4" X 4" $9,929 5 payments
  8. COLLAGENASE SANTYL $8,203 43 payments
  9. ALLEVYN LIFE L 15.4X15.4 CTN10 $7,029 3 payments
  10. OASIS MICRO $5,813 2 payments
  11. Other $39,767 239 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

60

Median for General Surgery: 59

Drug cost

$9,919

Median for General Surgery: $393

Branded share of claims

76.7%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 11 $9,564
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 35 $238
Ciprofloxacin Hcl Generic 14 $116

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$72,383

Medicare's payments for the services billed

Medicare patients

213

Average age 75

Services billed

955

125 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 50%
Depression 46%
Ischemic heart disease 44%
Chronic kidney disease 44%
Atrial fibrillation 42%
Heart failure 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kimyrsa
  • Melinta Therapeutics, Inc. $8
$8 — —
Orbactiv
  • Melinta Therapeutics, Inc. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

306 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record